Clinical Trial Monitoring and Quality Oversight
Monitoring verifies that subject rights and safety are protected and that data are accurate, complete, and verifiable against source. Candidates must understand risk-based monitoring - centralized and on-site components, key risk indicators, and targeted SDV - alongside traditional on-site monitoring. Know the purpose and content of monitoring plans, site visit reports and follow-up letters, source document verification, and query management.
Core concepts include source data review versus source data verification, protocol deviation and violation classification, CAPA (corrective and preventive action), root cause analysis, audit and inspection findings, and quality tolerance limits. Understand that monitoring is a continuous, risk-proportionate activity, not a calendar-driven checkbox.
Traps: treating every protocol deviation as a violation; confusing SDV (comparing source to CRF) with SDR (reviewing source for quality and compliance); and assuming centralized monitoring replaces on-site monitoring rather than complementing it. Another frequent trap is the question that presents a critical finding and asks for the first action - the answer is usually to protect subject safety and document, then escalate, not to immediately unblind or terminate the site.
Rule of thumb: when a monitoring finding involves potential harm, subject safety comes first, documentation second, escalation third, and corrective action fourth.
Worked example: During SDV, a CRA finds a subject received a prohibited concomitant medication. The CRA documents the finding, notifies the PI to assess the subject, files a deviation, and issues a follow-up letter - the site is not automatically closed.